Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ocular Therapeutix Q1 2026 Earnings Call - AXPAXLI Demonstrates Unprecedented Superiority in Wet AMD
Ocular Therapeutix delivered a transformative update on AXPAXLI (SOL-1), marking the first time a novel investigational therapy has statistically and clinically surpassed an approved anti-VEGF agent i...
- AXPAXLI (SOL-1) achieved statistical superiority over aflibercept in Phase III wet AMD with a p-value of 0.0006, marking the first time a novel investigational therapy has beaten an approved anti-VEGF in this indication.
- Unmatched durability: Two-thirds of patients maintained vision with a single injection for an entire year, while 66% sustained vision through 12 months in a highly treatment-naive, high-risk population.
- Superior disease control: AXPAXLI delayed time to fluid volume increases by 5-6 months compared to aflibercept, with a 6-month delay in reaching clinically meaningful rescue thresholds.
- +7 more takeaways
Labcorp Holdings Q1 2026 Earnings Call - Specialty Testing Momentum and Margin Expansion Drive Upside
Labcorp delivered a strong start to 2026, with Q1 revenue rising 5.8% to $3.5 billion and adjusted EPS climbing 10.6% to $4.25. The growth was broadly based, with Diagnostics Laboratories up 5% and Bi...
- Q1 2026 revenue reached $3.5 billion, up 5.8% year-over-year, with adjusted EPS growing 10.6% to $4.25.
- Organic revenue growth was 3.1%, driven by strong performance in both Diagnostics and Biopharma Laboratory Services segments.
- Diagnostics Laboratories revenue grew 5% to $2.8 billion, with 2.9% organic growth and a 2.6% price mix increase.
- +7 more takeaways
EVgo Q1 2026 Earnings Call - Record $110M Revenue and DOE Loan Amendment Fuel Aggressive Buildout
EVgo delivered record Q1 2026 revenue of $110 million, driven by a 45% year-over-year surge in its operating network and new dedicated AV hub contracts. The company added 200 new stalls, bringing tota...
- Record Q1 2026 revenue of $110 million, up 45% year-over-year, driven by network expansion and new AV hub contracts.
- Total stalls in operation reached 5,280, with 200 new stalls added in Q1, including 100 new public EVgo-owned stalls.
- Public network throughput hit 91 GWh in Q1, a 10% year-over-year increase, though daily per-stall throughput dipped 3.5% due to seasonal weather and new stall ramp-up.
- +9 more takeaways
Dorman Products Q1 2026 Earnings Call - Tariff Costs Weigh on Margins as Management Reaffirms Full-Year Guidance
Dorman Products reported a solid but margin-constrained first quarter, with net sales rising 4% to $529 million and adjusted EPS of $1.57, down 22% year-over-year. The decline was driven by the highes...
- Net sales rose 4% year-over-year to $529 million, driven by pricing actions that offset lower volumes against a strong prior-year quarter.
- Adjusted diluted EPS came in at $1.57, down 22% year-over-year, primarily due to elevated tariff-related cost of goods sold recognized via FIFO.
- Adjusted operating margin contracted to 12.1%, a 490 basis point decline, reflecting the peak tariff expense Dorman expects to recognize in 2026.
- +7 more takeaways
Atkore International Group Q2 FY2026 Earnings Call - Data Center & Solar Momentum Offsets PVC Headwinds
Atkore delivered a sequential improvement in Q2 FY2026, with net sales rising to $731 million and adjusted EPS of $1.23. The company’s earnings were weighed down by a $136.5 million pre-tax charge to ...
- Net sales rose 5% year-over-year to $731 million, marking the first quarterly sales increase since Q4 FY2022, driven by a 5% jump in organic volume and a 1.5% increase in average selling prices.
- Adjusted EPS came in at $1.23, significantly lower than the $2.04 reported in the prior year, primarily due to a $136.5 million pre-tax charge to settle two classes in PVC pipe antitrust litigation.
- Management confirmed full-year guidance remains intact, projecting mid-single-digit organic volume growth, adjusted EBITDA of $340 million to $360 million, and adjusted EPS of $5.05 to $5.55.
- +7 more takeaways
Revvity Q1 2026 Earnings Call - Divests China Immunodiagnostics to Focus on AI-Driven Life Sciences Growth
Revvity kicked off 2026 with a strong quarter, reporting 3% organic growth, adjusted operating margins of 23.6%, and EPS of $1.06, beating expectations. The defining move of the call was the decision ...
- Revvity reported Q1 2026 revenue of $711 million, with 3% organic growth, adjusted operating margins of 23.6%, and adjusted EPS of $1.06, all beating guidance.
- The company announced a strategic divestiture of its China immunodiagnostics business, which represented ~6% of 2025 revenue, due to persistent policy headwinds and high capital requirements for local manufacturing.
- Pro forma Q1 organic growth excluding China immunodiagnostics would have been 6%, with pro forma adjusted operating margins of 24% and EPS of $1.04.
- +11 more takeaways
Texas Capital Bancshares Q1 2026 Earnings Call - Record Fee Income and Dividend Initiation Signal Platform Maturity
Texas Capital Bancshares delivered a quarter defined by structural momentum rather than cyclical luck. Fee income hit a record $58.8 million, driven by an 89% surge in investment banking and broad-bas...
- Fee income reached a record $58.8 million in Q1 2026, up 59% year-over-year, with all three focus areas—investment banking, treasury, and wealth management—delivering record quarterly contributions.
- Investment banking fees surged 89% year-over-year to $42.3 million, supported by $11 billion in debt arrangements and over $1 billion in equity raises, highlighting the firm's role as a top middle-market arranger.
- Texas Capital Bancshares initiated a quarterly common stock dividend of $0.20 per share, signaling confidence in sustainable earnings and a shift toward mature capital return policies.
- +7 more takeaways
James River Group Holdings Q1 2026 Earnings Call - Earnings Dented by Reinsurance Charge, But Core Underwriting Remains Disciplined
James River Group Holdings reported a net loss of $10.9 million for Q1 2026, a sharp reversal from the $7.6 million net income in the prior year period. The result was heavily distorted by a $6.7 mill...
- Net loss of $10.9 million reported for Q1 2026, compared to $7.6 million net income in Q1 2025.
- A $6.7 million reinsurance reinstatement charge on a legacy 2022 casualty treaty drove the loss, adding ~5 points to the combined ratio.
- Excluding the reinstatement charge, operating earnings would have been $0.22 per diluted share, with a consolidated combined ratio of 99.7%.
- +10 more takeaways
California Water Service Group Q1 2026 Earnings Call - Revised Rate Case Approval Drives Infrastructure Momentum
California Water Service Group delivered Q1 2026 results that were squarely in line with expectations, despite a delayed General Rate Case. The highlight of the quarter was a 17.6% jump in infrastruct...
- Q1 2026 revenue reached $214.6 million, up from $204.0 million in the prior year period.
- Net income for Q1 2026 was $4.0 million, or $0.07 per diluted share, down from $13.3 million, or $0.22 per diluted share, in Q1 2025.
- Infrastructure capital investments surged 17.6% to $129.5 million in Q1, with total planned 2026 capital expenditures set at $627 million.
- +12 more takeaways
Crocs Q1 2026 Earnings Call - New Product Momentum Offsets Tariff and Geopolitical Headwinds
Crocs delivered a better-than-expected first quarter, posting $921 million in revenue despite a 2% reported decline, driven by strong direct-to-consumer growth and international expansion. Both the Cr...
- Total revenue of $921 million came in ahead of expectations, despite a 2% reported decline and 4% constant-currency drop, fueled by strong direct-to-consumer performance.
- Crocs brand revenue fell 2% to $767 million, but DTC grew 11% in North America despite pulling back on promotions, signaling product-led demand.
- HEYDUDE brand revenue declined 13% to $154 million, yet DTC rose 8% on lower performance marketing spend, indicating improving brand health and efficiency.
- +9 more takeaways